MNOV MEDICINOVA INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1226616 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.2%
TTM EPS YoY16.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,232.2%
Net margin-1,127.0%
FCF margin-1,047.7%
EBITDA margin-1,230.3%
Returns
ROE-24.8%
ROA-22.7%
ROIC (approx.)-78.4%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio8.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $138,555 | $458,439 | $186,984 | $151,739 | $123,319 | $134,599 | — | — |
| R&D expense | $1.10M | $900,000 | $1.20M | $1.40M | $1.50M | $2.00M | $1.70M | $1.80M |
| SG&A expense | $1.87M | $1.83M | $1.59M | $1.55M | $1.81M | $1.44M | $1.36M | $1.28M |
| Operating income | -$3.06M | -$2.54M | -$2.84M | -$3.09M | -$3.38M | -$3.61M | -$3.20M | -$3.18M |
| Net income | -$2.84M | -$2.31M | -$2.59M | -$2.80M | -$3.05M | -$3.28M | -$2.86M | -$2.81M |
| EBITDA | -$3.06M | -$2.54M | -$2.83M | -$3.09M | -$3.38M | -$3.60M | -$3.20M | -$3.18M |
| EPS (basic) | -0.06 | -0.05 | -0.05 | — | -0.06 | -0.07 | -0.06 | — |
| EPS (diluted) | -0.06 | -0.05 | -0.05 | — | -0.06 | -0.07 | -0.06 | — |
| Weighted avg. shares (diluted) | 49.38M | 49.22M | 49.22M | — | 49.05M | 49.05M | 49.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.26M | $25.42M | $27.33M | $30.81M | $32.56M | $34.26M | $36.57M | $40.36M |
| Receivables | $600,584 | $0 | $245,100 | $0 | $0 | $134,599 | — | $0 |
| Current assets | $30.23M | $25.92M | $28.15M | $30.99M | $32.92M | $35.12M | $37.68M | $41.07M |
| PP&E, net | $6,457 | $9,829 | $14,878 | $8,340 | $12,933 | $15,361 | $20,386 | $25,507 |
| Goodwill | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M |
| Total assets | $45.24M | $40.43M | $42.70M | $45.60M | $47.58M | $49.82M | $52.43M | $55.88M |
| Current liabilities | $3.46M | $2.96M | $3.10M | $3.80M | $3.34M | $2.65M | $2.13M | $2.96M |
| Total liabilities | $4.15M | $3.16M | $3.30M | $4.02M | $3.61M | $2.97M | $2.50M | $3.37M |
| Shareholders' equity | $41.09M | $37.27M | $39.41M | $41.59M | $43.96M | $46.86M | $49.93M | $52.50M |
| Shares outstanding | 51.23M | 49.22M | 49.22M | 49.22M | 49.05M | 49.05M | 49.05M | 49.05M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.39M | -$1.92M | -$3.47M | -$2.02M | -$1.70M | -$2.31M | -$3.78M | -$1.93M |
| Capital expenditure | $0 | $0 | $10,825 | $0 | $2,899 | $0 | $0 | -$2 |
| Free cash flow | -$2.39M | -$1.92M | -$3.48M | -$2.02M | -$1.71M | -$2.31M | -$3.78M | -$1.93M |
| Investing cash flow | $0 | $0 | -$10,825 | $0 | -$2,899 | $0 | $0 | $1 |
| Financing cash flow | — | — | — | $244,018 | — | — | — | — |
| Depreciation & amortization | $3,419 | $5,020 | $4,260 | $4,555 | $5,303 | $5,064 | $5,177 | $5,177 |
| Stock-based compensation | $430,879 | $176,767 | $407,761 | $180,563 | $157,692 | $204,897 | $285,943 | $263,993 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.